Raffles Associates’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.47M	Hold	5,362,788	–	–	7.35%	2
2025 Q4	$8.96M	Sell	5,362,788 -25,000	-0.5%	-$43.3K	6.72%	4
2025 Q3	$9.11M	Sell	5,387,788 -4,300	-0.1%	-$5.09K	8.48%	2
2025 Q2	$4.89M	Sell	5,392,088 -250,000	-4%	-$148K	5.1%	7
2025 Q1	$2.55M	Buy	5,642,088 +150,000	+3%	+$88K	3.1%	10
2024 Q4	$2.76M	Buy	5,492,088 +984,307	+22%	+$723K	2.97%	12
2024 Q3	$4.08M	Buy	4,507,781 +150,000	+3%	+$139K	4.19%	9
2024 Q2	$4.35M	Buy	4,357,781 +1,147,800	+36%	+$1.27M	4.9%	8
2024 Q1	$4.75M	Buy	3,209,981 +1,078,360	+51%	+$1.22M	5.51%	6
2023 Q4	$2.32M	Buy	2,131,621 +543,882	+34%	+$596K	2.94%	10
2023 Q3	$1.87M	Sell	1,587,739 -10,000	-0.6%	-$13.6K	2.48%	14
2023 Q2	$2.25M	Buy	1,597,739 +60,793	+4%	+$84K	3.03%	10
2023 Q1	$2.31M	Hold	1,536,946	–	–	3.14%	11
2022 Q4	$1.8M	Sell	1,536,946 -543,590	-26%	-$685K	2.1%	13
2022 Q3	$2.35M	Buy	2,080,536 +150,000	+8%	+$220K	2.52%	11
2022 Q2	$3.05M	Buy	1,930,536 +624,441	+48%	+$823K	3.32%	10
2022 Q1	$2.01M	Buy	1,306,095 +762,505	+140%	+$1.18M	2.07%	13
2021 Q4	$1.33M	Buy	543,590 +450,000	+481%	+$1.05M	1.28%	19
2021 Q3	$236K	Buy	93,590 +50,000	+115%	+$128K	0.22%	39
2021 Q2	$124K	Hold	43,590	–	–	0.11%	43
2021 Q1	$102K	Buy	+43,590	New	+$105K	0.1%	36
2018 Q3	–	Sell	-51,435	Closed	-$93K	–	52
2018 Q2	$93K	Buy	+51,435	New	+$104K	0.08%	50

Other funds holding LCTX